The European Union’s drug regulator—the EU equivalent of the FDA.The EMA evaluates and supervises medicines across the European Economic Area. Marketing authorization through the EMA’s centralized procedure grants approval in all EU member states simultaneously. For peptide therapeutics, EMA and FDA approval timelines often diverge—compounds may be approved in one jurisdiction years before the other, creating access disparities that affect clinical practice and research availability.